AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

A significant minority of patients with brain metastases may avoid radiotherapy, but they need to be carefully selected.

The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Tuesday said their cancer drug Enhertu received a priority review by the Food & Drug Administration in the US for some forms of breast ...

That comes amid mixed results for its experimental drug with partner Daiichi Sankyo Co., and analyst concerns about the ...

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

Older adults treated for cancer had double the risk of cardiovascular (CV) events, including stroke, as compared with those ...

Prices for prescription pharmaceutical drugs have skyrocketed, disproportionately making them harder for people of color to ...